INDOUS — Indo US Bio-Tech Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapFalling Star

Annual income statement for Indo US Bio-Tech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	401	501	617	728	1,038
Cost of Revenue
Gross Profit	148	139	166	235	312
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	348	438	532	628	860
Operating Profit	52.6	63	85.5	99.9	178
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	41.3	53.1	73.9	88	165
Provision for Income Taxes
Net Income After Taxes	51	50.6	72.4	82.5	163
Net Income Before Extraordinary Items
Net Income	51	50.6	72.4	82.5	163
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	51	50.6	72.4	82.5	163
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.51	4.14	3.75	4.11	8.12
Dividends per Share